Evaluation of the Comet Assay for Assessing the Dose-Response Relationship of DNA Damage
Dose response relationship
-
Upload
mohamed-sanooz -
Category
Health & Medicine
-
view
1.011 -
download
0
Transcript of Dose response relationship
![Page 1: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/1.jpg)
Dose-Response Relationship
Dr. Sanooz Raheem
![Page 2: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/2.jpg)
Objectives 1. Describe dose response relationship2. Explain therapeutic window phenomenon 3. Define a. drug potency b. drug efficiency 4. Define therapeutic index and its clinical importance
![Page 3: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/3.jpg)
Dose-Response Relationship• When a Drug administered systemically
• Dose-plasma concentration relationship (determined by pharmacokinetic properties)
• Plasma concentration (dose)-response relationship• Intensity of response increases with increase in dose / concentration at the
receptor • Drug-receptor interaction obeys law of mass action
![Page 4: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/4.jpg)
Emax * [D]
E=KD +[D]
E- observed effectD- dose Emax- maximal response Kd- dissociation constant of the drug-receptor complex
![Page 5: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/5.jpg)
Dose-Response CurveE =
Emax X [D]
Kd + [D]
Dose-response and log dose-responsecurves
![Page 6: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/6.jpg)
Dose- Response curve• Response is proportional to an exponential function(log) of the dose • Advantages:- A wide range of drug doses can be easily displayed on a graph- Comparison between agonists and study of antagonists becomes
easier
![Page 7: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/7.jpg)
Drug Potency and efficacy• Potency: amount of drug required to produce a certain response
DRC positioned rightward indicates a lower potency Relative potency is more meaningful than absolute potency Relative potency: comparing the dose of two agonists at which they elicit half
maximal response (EC50)Ex: 10mg of morphine= 100 mg pethidine as analgesic , morphine is potent • Potency for therapeutic effect should increase over the potency for adverse effects • Potency of a drug important to choose a dose
![Page 8: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/8.jpg)
• Efficacy: Maximal response that can be elicited by the drug Ex: morphine produces analgesia not reached with any dose of aspirin.
Morphine is more efficacious than aspirin.
Efficacy is an important factor in the choice of a drug
![Page 9: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/9.jpg)
Illustration of drug potency and drug efficacy.Dose-response curve of four drugs producing the samequalitative effect
Potency and efficacy1.Compare drug A&B2.A&C3.D vs A,B,C
![Page 10: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/10.jpg)
Note:Drug B is less potent but equally efficacious as drug A.Drug C is less potent and less efficacious than drug ADrug D is more potent than drugs A, B, & C, but less efficaciousthan drugs A & B, and equally efficacious as drug C
![Page 11: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/11.jpg)
Potency and efficacy - Examples• Aspirin is less potent as well as less efficacious than Morphine• Pethidine is less potent analgesic than Morphine but equally efficacious• Diazepam is more potent but less efficacious than pentobarbitone• Furosemide is less potent but more efficacious than metolazone
• Depending on the type of drug, both higher efficacy or lower efficacy could be clinically advantageous.
![Page 12: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/12.jpg)
Slope of DRC• Steep slope – moderate increase in dose markedly increase the response (dose needs
individualization)• Flat DRC – little increase in response occurs in wide range of doses (standard dose can be given to
most patients)• Example: Hydralazine and Hydrochlorothiazide DRC in Hypertension
Steep and flat dose-response curves illustratedby antihypertensive effect of hydralazine and hydrochlorothiazide
![Page 13: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/13.jpg)
Therapeutic efficacy • Depends on- Relative potency and efficacy - Pharmacokinetic variables- Pathophysiological variables
• Expressed in terms ofa.Degree of benefit/ relief afforded by the drug orb.Success rate in achieving a defined therapeutic end point Ex: a drug which makes a higher percentage of epileptic patients totally
seizure free than another drug is the more therapeutically effective antiepileptic.
![Page 14: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/14.jpg)
Drug Selectivity • Some drugs may produce different actions • DRCs for different effects of drug may be different • Extent of separation of DRCs of a drug for different effects is a
measure of its selectivity Ex: Isoprenaline vs salbutamol
![Page 15: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/15.jpg)
Illustration of drug selectivity.Log dose-response curves of salbutamol for bronchodilatation(A) and cardiac stimulation (D)Log dose-response curves of isoprenaline for bronchodilatation(B) and cardiac stimulation (C)
![Page 16: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/16.jpg)
Therapeutic index (TI)/ Safety margin
Gap between the therapeutic effect DRC and adverse effect DRC Median effective dose- dose which
produces the Specified effect in 50% individuals Median lethal dose- dose which kills 50% of the recipients
![Page 17: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/17.jpg)
Therapeutic index (TI)
![Page 18: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/18.jpg)
Therapeutic window/ therapeutic range • Bounded by the dose which produces minimal therapeutic effect and
the dose which produces maximal acceptable adverse effect• Individual variability: effective dose may be toxic for others • Defining the therapeutic range is difficult • Few drugs higher therapeutic response and adverse effects in higher
dosesEx: Prednisolone in Asthma
![Page 19: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/19.jpg)
Illustrative dose-response curves for therapeuticeffect and adverse effect of the same drug
![Page 20: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/20.jpg)
Risk-benefit ratio• Judgment between estimated harm and the expected advantages • Estimated harms:- Adverse effects- Cost - Inconvenience • Expected advantages:- Relief of symptoms- Cure - Reduction in complications/mortality - Improvement in quality of life
![Page 21: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/21.jpg)
• Prescribe when benefit outweighs the risks• Difficult to measure accurately • Should rely on pharmacoepidemiology and experience
![Page 22: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/22.jpg)
Drug specificity • Refers to range of actions produced by a drug • Drugs may show – - One / limited number of actions- Widespread effects on many organs of the body • Depends on:a.Whether drug acts on single/many receptors/targets and b.How widely the target is distributed in the body Ex:Omeprazole- highly selectiveChlorpromazine- D2, muscarinic cholinergic, H1, 5-HT Dexamathasone- involves many organs due to receptors widespread in the
body
![Page 23: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/23.jpg)
Combined effects of drugs
![Page 24: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/24.jpg)
objectives• Describe the combined effects of drug action• Explain synergism with few examples• Explain antagonism with few examples
![Page 25: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/25.jpg)
Combined effects of drugs • If two/ more drugs given simultaneously/ in quick succession, they
may be either indifferent to each other or exhibit synergism/ antagonism.
• Interaction may take place at- Pharmacokinetic level- Pharmacodynamic level
![Page 26: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/26.jpg)
Synergism • Action of one drug is facilitated or increased by the other • In a synergetic pair- Both drugs can have action in same direction or- One may be inactive and enhancing the effect of other • Two types - Additive- Supraadditive/ potentiation
![Page 27: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/27.jpg)
Additive • Effect of two drugs in same direction and simply adds up
Effects of drugs A+B= effect of drug A+ effect of drug BSide effects do not add up Better tolerance than high dose of one component
![Page 28: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/28.jpg)
Supraadditive • Effect of combination is greater than the individual effects
Effects of drug A+B > effect of drug A+ effect of drug B When one component given alone produces no effect, but
enhances the effect of the other.
![Page 29: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/29.jpg)
![Page 30: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/30.jpg)
Antagonism • One drug decreases or abolishes the action of the other
Effects of A+B < effect of drug A+ effect of drug B • One drug is inactive and decreases the effect of the other
![Page 31: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/31.jpg)
Drug Antagonism1. Physical2. Chemical3. Physiological antagonism4. Receptor antagonism:
a. Competitive antagonism (equilibrium)b. Non-competitivec. Non-equilibrium
![Page 32: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/32.jpg)
Physical antagonism • Based on the physical property of the drug
- charcoal : adsorbs alkaloids (used in alkaloidal poisonings)
![Page 33: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/33.jpg)
Chemical antagonism • Two drugs react chemically and form an inactive product
![Page 34: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/34.jpg)
Physiological/ functional antagonism • Two drugs act on different receptors or by different mechanisms • Have opposite effects on the same physiological function
![Page 35: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/35.jpg)
Receptor antagonism • One drug/ antagonist blocks the receptor action of the other
drug/agonist • Receptor antagonists are relatively selective
![Page 36: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/36.jpg)
Receptor antagonism - curvesCompetitive:
o Antagonist is chemically similar to agonist and binds to same receptor molecules
o Affinity (1) but IA (0), Result – no responseo Log DRC shifts to the righto antagonism is reversible – increase in concentration of agonist overcomes
the blocko Parallel shift of curve to the right side when the concentration of antagonist
increases o Extent of shift depends on affinity and concentration of antagonist
![Page 37: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/37.jpg)
![Page 38: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/38.jpg)
Plot on a DRC for competitive antagonists A&B. Antagonism A>B, Agonist notify as C
![Page 39: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/39.jpg)
Dose-response curves showing competitive (a) antagonismA—agonist, B—competitive antagonist,
![Page 40: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/40.jpg)
* Partial agonist- have affinity for the same receptor competes with and antagonizes a full agonist & produces a submaximal response
![Page 41: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/41.jpg)
Non-competitive/ allosteric antagonism:o Allosteric site binding- altering receptor not to bind with
agonist/ unable to transduce the response o Chemically unrelated to antagonist o No competition between them – no change of effect even
agonist concentration is increasedo Increasing concentration of antagonist progressively flatten DRCo Not in clinical use
![Page 42: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/42.jpg)
![Page 43: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/43.jpg)
Plot on a graph for non-competitive antagonists A&B, Antagonism A>B, Agonist notify as C
![Page 44: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/44.jpg)
![Page 45: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/45.jpg)
• Non – equilibrium:• Antagonists Binds receptor with strong bond• Dissociation is slow and agonists cannot displace antagonists• Irreversible antagonism develops• DRC shifts to the right and Maximal response lowered• Phenoxybenzamine is a non-equilibrium antagonist of adrenaline
at the alpha adrenergic receptors
![Page 46: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/46.jpg)
Plot on a DRC for agonist A and non-equilibrium antagonist B
![Page 47: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/47.jpg)
Compare between competitive and non-competitive antagonists?
![Page 48: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/48.jpg)
![Page 49: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/49.jpg)
![Page 50: Dose response relationship](https://reader036.fdocuments.in/reader036/viewer/2022081414/588393fd1a28ab2b568b4873/html5/thumbnails/50.jpg)
THANK YOU